Domainex wins Ark discovery contract renewal

- Last updated on GMT

Related tags: Pharmacology

UK-based contract research services provider Domainex has extended its discovery and lead optimisation contract with drug developer Ark Therapeutics.

Domainex has worked with Ark for several years, specifically applying its medicinal chemistry, molecular biology and computer-aided drug design services to therapeutic preclinical targets nominated by Ark.

Trevor Perrior, Domainex’ research director, said that: “The synergy and teamwork between our respective scientists have been outstanding, and this collaboration has already resulted in the achievement of key breakthroughs against very challenging scientific goals​.”

Earlier this week Domainex’ LeadBuilder screening technology was selected by scientists at St George’s University of London and the University of Manchester for an asthma research programme focused on the Der p1 enzyme linked to the disease.

Related topics: Preclinical Research, Preclinical

Related news

Show more

Related product

Global Clinical Trial Lab Services

Global Clinical Trial Lab Services

Q² Solutions | 01-Apr-2020 | Product Presentation

As a leading global lab services partner, we provide operational excellence, scientific leadership and innovation through technology. We offer end-to-end...

Related suppliers

Follow us

Products

View more

Webinars